Overall, the findings suggest that TMB, mainly when defined with higher thresholds (such as 16 mutations per mega-base using the TSO500 assay), can serve as a critical biomarker for predicting the efficacy of anti-PD-L1 therapy in a wide range of tumors, including CCA [35]. The gene discussed is CD274; the disease is cholangiocarcinoma.